9688Zai Lab9688 info
$2.09info0.49%24h
Global rank5077
Market cap$2.07B
Change 7d-
YTD Performance-24.62%
SP500 benchmarkUnderperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Main Sector
Healthcare
Business data

    Zai Lab (9688) Stock Overview

    Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. Its commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. The company also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naΓ―ve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, it develops Zipalertinib for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; ZL-2313, an investigational oral EGFR inhibitor; ZL-1211, a humanized IgG1 monoclonal antibody that targets CLDN18.2; ZL-1218 is humanized IgG1 monoclonal antibody to induce potent antibody-dependent cellular cytotoxicity activity that enables NK cell-mediated killing of CCR8-expressing T-regs; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter; and KarXT for the treatment of psychiatric and neurological conditions. The company was incorporated in 2013 and is headquartered in Shanghai, China.

    9688 Stock Information

    Symbol
    9688
    Address
    Jinchuang PlazaShanghai, 201210China
    Founded
    -
    Trading hours
    -
    Website
    https://www.zailaboratory.com
    Country
    πŸ‡¨πŸ‡³ China
    Phone Number
    86 21 6163 2588

    Zai Lab (9688) Price Chart

    -
    Value:-

    Zai Lab Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $2.09
    N/A
    Market Cap
    $2.07B
    N/A
    Shares Outstanding
    988.39M
    N/A
    Employees
    2.04K
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    Β© 2024 Topstocks.org